Global Autoimmune Disease Testing Market Size study & Forecast, by Product Type (Instruments, Reagents & Consumables), by Disease Type (Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Scleroderma, Vasculitis, Inflammatory Bowel Disease (IBD

Global Autoimmune Disease Testing Market Size study & Forecast, by Product Type (Instruments, Reagents & Consumables), by Disease Type (Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Scleroderma, Vasculitis, Inflammatory Bowel Disease (IBD), Others), by Test Type (Antinuclear Autoantibody (ANA), Rheumatoid Factor (RF), C-Reactive Protein (CRP), Anti-Thyroglobulin Antibody (ATA), Others), by End-User (Hospital & Clinics, Diagnostic Centers, Others), and Regional Analysis 2023-2030

Global Autoimmune Disease Testing Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over during the forecast period 2023-2030. Autoimmune disease testing encompasses a variety of diagnostic procedures aimed at identifying and evaluating autoimmune conditions, where the body's immune system mistakenly attacks its own tissues. These tests include blood tests to measure specific antibodies and proteins indicative of autoimmune activity, autoantibody tests to detect antibodies targeting the body's tissues, imaging tests to visualize affected organs, and sometimes biopsies for tissue examination. Prompt and accurate autoimmune disease testing is crucial for early diagnosis, monitoring disease progression, and guiding appropriate treatment strategies. Early detection enables timely intervention to manage symptoms and prevent complications, leading to improved patient outcomes and quality of life. Basic tests including antinuclear autoantibody, rheumatoid Rheumatoid factor Factor (RF), and others so on are frequently required for the diagnosis of autoimmune illnesses. These tests assist manage and diagnose autoimmune disease patients, offer a prognosis, or reveal the extent of organ involvement or damage. The growing awareness regarding autoimmune diseases, rising automation in a laboratory, and the introduction of novel products for autoimmune disease diagnostics are the key factors that are stipulating the market demand during the estimated years of 2023-2030.

In addition, the rising prevalence of autoimmune diseases is acting as a major driving factor for market growth across the globe . For instance, according to According to an NCBI article from September 2022, the incidence of rheumatoid arthritis was reported at 24 cases per 100,000 people in Northern Europe and 36 cases per 100,000 people in Northern America. Likewise, another NCBI article published in 2021 indicated a global increase in osteoarthritis prevalence, ranging from 8.5% to 9.3% in 2021.the NCBI article published in September 2022, the incidence of rheumatoid arthritis in Northern Europe and Northern America was 24 and 36 cases per 100,000 people, respectively. Similarly, another NCBI article published in 2021 mentioned that globally, osteoarthritis prevalence increased by 8.5%-9.3% in 2021. Thus, the increasing prevalence of autoimmune diseases these aforementioned factors are likely to augment the market growth at a substantial rate. Further, the rising adoption of biosensors for autoimmune disease testing, as well as growing expenditure on R&D activities are leveraging various opportunities over the forecasting forecast years. However, the lack of penetration of these products in developing regions and lack of awareness of these diseases amongst the general population stifles market growth throughout the forecast period of 2022-2030.

The key regions considered for the Global Autoimmune Disease Testing Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing focus on R&D for the development of new testing options and the presence of leading market players. Moreover, strategic initiatives in this region have propelled it to a leading market position. For example, in January 2020, Progentec Diagnostics, Inc. secured USD 5 million in funds. The company intends to utilize this investment to create an extensive solution for effectively managing lupus patients through highly sensitive and specific continuous remote digital monitoring. Furthermore, the growing emphasis on research and development to introduce novel testing options is expected to bolster regional market growth in the forecast period. Whereas, the Asia Pacific is expected to grow with the highest CAGR during over the forecast period, owing to factors such as the rising prevalence of target diseases, as well as the increasing geriatric population in the regional market.

Major market players included in this report are:
F. Hoffmann-La Roche Ltd
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Abbott
Werfen
Trinity Biotech PLC
Bio-Rad Laboratories, Inc.
ORGENTEC Diagnostika GmbH
Cambridge Life Sciences Limited

Recent Developments in the Market:
 In March 2022, Siemens Healthcare GmbH unveiled that the company received the designation of an innovative device for its ADVIA Centaur serum Neurofilament Light Chain (sNfL) assay, which was advanced with the collaboration with Novartis AG to identify adult patients with multiple sclerosis.
 In May 2022, Thermo Fisher Scientific Inc. announced that its new Phadia 2500+ range of instruments are is available throughout the United States. These devices are used to check people with autoimmune diseases, including autoimmune thyroid illness, autoimmune liver disease, rheumatoid arthritis, and celiac disease.The devices are used to examine patients with autoimmune conditions such celiac disease, rheumatoid arthritis, autoimmune liver disease, and autoimmune thyroid illness.

Global Autoimmune Disease Testing Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product Type, Disease Type, Test Type, End-user, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product Type:
Instruments
Reagents & Consumables

By Disease Type:
Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE)
Scleroderma
Vasculitis
Inflammatory Bowel Disease (IBD)
Others

By Test Type:
Antinuclear Autoantibody (ANA)
Rheumatoid Factor (RF)
C-Reactive Protein (CRP)
Anti-Thyroglobulin Antibody (ATA)
Others

By End-User:
Hospital & Clinics
Diagnostic Centers
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.